Glaucoma Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Glaucoma Treatment Market By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Congenital Glaucoma, Secondary Glaucoma, and Others), By Drug Class (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Carbonic Anhydrase Inhibitors, and Others), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Glaucoma Treatment Market size was valued at USD 7.91 Billion in 2020 and is projected to reach USD 13.53 Billion by 2027, growing at a CAGR of 6.98% from 2021 to 2027. Glaucoma is known as the silent thief of sight because most kinds of the disease generate no discomfort or symptoms until significant vision loss occurs. Glaucoma is a collection of eye illnesses that develop when the optic nerve, which transmits information from the eye to the brain, is damaged. The majority of cases are linked to ocular hypertension, a condition in which the pressure inside the eye is higher than normal, although it can also happen when the intraocular pressure is normal. If left untreated, it causes peripheral vision loss, which then progresses to permanent blindness. Glaucoma is the world’s second largest cause of blindness. During normal eye exams, a tonometer is used to measure intraocular pressure (IOP). IOP should be less than 21 mmHg in most cases. Glaucoma treatment options include surgery, laser treatment, and medication, depending on the severity of the condition. The majority of eye drops are used to reduce IOP, which is the initial line of defence against glaucoma. Most people are casual about using eye drops correctly, and failing to take prescribed prescription is a primary cause of blindness. Glaucoma Treatment Market owing to rising prevalence of Glaucoma. For instance, WHO estimates that 4.5 million people are blind due to Glaucoma. In India, Glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. Moreover, around 90+ percent of the cases of the glaucoma are undiagnosed in the community. In 2010, around 1.9% of the people in United States age 40 and older. Additionally, technological advancements in the field of ophthalmology and increasing initiatives regarding the awareness of Glaucoma to make aware of the deadly disease. For instance, in March 2020, theme named “sneak thief of sight” has been hosted at Gandhi Thidal as part of a campaign to raise glaucoma awareness. In India, only 5-10% of the people are aware of the disease. However, stringent approval process coupled with the side effects associated with the products are the major factors hampering the growth of the market.

 


Glaucoma Treatment Market

MARKET SUMMARY
-
6.98%
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 6.98%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Glaucoma Treatment Market

  • The report on global glaucoma treatment market gives historical, current, and future market sizes (US$ Bn) on the basis of indication, drug class, sales channel, and region.
  • This report studies global glaucoma treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
  • In addition, global glaucoma treatment market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
  • Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
  • Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global glaucoma treatment.
Market Key Players
  • Novartis AG
  • Akorn, Incorporated
  • Inotek Pharmaceuticals
  • Aerie Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Abbvie Inc. (Allergan Plc)
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health (Bausch & Lomb Incorporated)
  • Teva Pharmaceuticals
Growth

Glaucoma Treatment Market

Glaucoma is the second leading cause of blindness, globally and is the top cause of irreversible blindness in the world. For instance, According to WHO estimates, more than 60 million patients are suffering from glaucoma worldwide, as per 2019 statistics. According to the Glaucoma Research Foundation, in the United States, more than 120,000 patients are blind from glaucoma. Thus, owing to the increasing cases of glaucoma the market is anticipated to witness high growth over the forecast period.


North-America Got Significant Share

Glaucoma Treatment Market

Global glaucoma treatment market report gives comprehensive outlook on glaucoma treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2019, North America contributed highest share of revenue followed by Europe, and Asia Pacific in the global glaucoma treatment market. North America region is anticipated to grow with a significant CAGR over the forecast years owing to increasing prevalence of Glaucoma coupled with the adoption of innovative products is the major factor driving the growth of the market over the forecast years. Well-established healthcare infrastructure and increasing awareness regarding the Glaucoma in the region are the main factors driving the growth of the market. Moreover, presence of large number of prominent players in the region and launch of new products continuously in the market fuels the growth of the market. Europe market has registered significant market share in 2019 and is estimated to grow with a CAGR of 4.9% over the forecast years.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Key

Key Findings of the Report

Glaucoma Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Novartis AG
  • Akorn, Incorporated
  • Inotek Pharmaceuticals
  • Aerie Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Abbvie Inc. (Allergan Plc)
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health (Bausch & Lomb Incorporated)
  • Teva Pharmaceuticals

 

Description

Global Glaucoma Treatment Market size was valued at USD 7.91 Billion in 2020 and is projected to reach USD 13.53 Billion by 2027, growing at a CAGR of 6.98% from 2021 to 2027. Glaucoma is known as the silent thief of sight because most kinds of the disease generate no discomfort or symptoms until significant vision loss occurs. Glaucoma is a collection of eye illnesses that develop when the optic nerve, which transmits information from the eye to the brain, is damaged. The majority of cases are linked to ocular hypertension, a condition in which the pressure inside the eye is higher than normal, although it can also happen when the intraocular pressure is normal. If left untreated, it causes peripheral vision loss, which then progresses to permanent blindness. Glaucoma is the world’s second largest cause of blindness. During normal eye exams, a tonometer is used to measure intraocular pressure (IOP). IOP should be less than 21 mmHg in most cases. Glaucoma treatment options include surgery, laser treatment, and medication, depending on the severity of the condition. The majority of eye drops are used to reduce IOP, which is the initial line of defence against glaucoma. Most people are casual about using eye drops correctly, and failing to take prescribed prescription is a primary cause of blindness. Glaucoma Treatment Market owing to rising prevalence of Glaucoma. For instance, WHO estimates that 4.5 million people are blind due to Glaucoma. In India, Glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. Moreover, around 90+ percent of the cases of the glaucoma are undiagnosed in the community. In 2010, around 1.9% of the people in United States age 40 and older. Additionally, technological advancements in the field of ophthalmology and increasing initiatives regarding the awareness of Glaucoma to make aware of the deadly disease. For instance, in March 2020, theme named “sneak thief of sight” has been hosted at Gandhi Thidal as part of a campaign to raise glaucoma awareness. In India, only 5-10% of the people are aware of the disease. However, stringent approval process coupled with the side effects associated with the products are the major factors hampering the growth of the market.

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX